Financial Comparison: Helius Medical Technologies (NASDAQ:HSDT) versus InMode (NASDAQ:INMD)

Helius Medical Technologies (NASDAQ:HSDTGet Rating) and InMode (NASDAQ:INMDGet Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Profitability

This table compares Helius Medical Technologies and InMode’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Helius Medical Technologies -1,741.55% -148.27% -108.20%
InMode 40.93% 39.52% 34.40%

Risk & Volatility

Helius Medical Technologies has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, InMode has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.

Institutional & Insider Ownership

9.6% of Helius Medical Technologies shares are owned by institutional investors. Comparatively, 54.9% of InMode shares are owned by institutional investors. 11.2% of Helius Medical Technologies shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Helius Medical Technologies and InMode’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Helius Medical Technologies $520,000.00 17.79 -$18.13 million ($3.55) -0.09
InMode $357.57 million 8.41 $164.97 million $2.07 17.44

InMode has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Helius Medical Technologies and InMode, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helius Medical Technologies 0 0 1 0 3.00
InMode 0 0 4 0 3.00

Helius Medical Technologies presently has a consensus target price of $5.00, indicating a potential upside of 1,424.39%. InMode has a consensus target price of $46.60, indicating a potential upside of 29.05%. Given Helius Medical Technologies’ higher possible upside, research analysts plainly believe Helius Medical Technologies is more favorable than InMode.

Summary

InMode beats Helius Medical Technologies on 10 of the 13 factors compared between the two stocks.

About Helius Medical Technologies

(Get Rating)

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

About InMode

(Get Rating)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.